Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -110.02% is in line with its 5-year average of -103.96%, around the middle of its 5-year range (-194.93%–-0.13%).
16.26% above its 12-month average of -131.38%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2026 (2026-05-31): -162.51%.
EBITDA MARGIN
-110.02%
EBITDA MARGIN AVG TTM
-131.38%
EBITDA MARGIN AVG 3Y
-116.79%
EBITDA MARGIN AVG 5Y
-103.96%
EBITDA MARGIN AVG 10Y
-73.23%
EBITDA MARGIN AVG 15Y
-49.33%
EBITDA MARGIN AVG 20Y
-30.47%
CURRENT VS TTM AVG
+16.26%
CURRENT VS 3Y AVG
+5.80%
CURRENT VS 5Y AVG
-5.83%
CURRENT VS 10Y AVG
-50.24%
CURRENT VS 15Y AVG
-123.03%
CURRENT VS 20Y AVG
-261.03%
Biomerica, Inc.
Market Cap
$6.34M
EBITDA Margin
-110.02%
TTM Avg
-131.38%
3Y Avg
-116.79%
5Y Avg
-103.96%
Market Cap
$6.44M
EBITDA Margin
-485.73%
TTM Avg
-485.73%
3Y Avg
-485.73%
5Y Avg
-485.73%
Market Cap
$6.10M
EBITDA Margin
-729.87%
TTM Avg
-884.05%
3Y Avg
-981.20%
5Y Avg
-851.95%
Market Cap
$6.10M
EBITDA Margin
-41051.94%
TTM Avg
-32118.88%
3Y Avg
-145781.05%
5Y Avg
-130042.11%
Market Cap
$6.09M
EBITDA Margin
-417.17%
TTM Avg
-417.17%
3Y Avg
-417.17%
5Y Avg
-417.17%
Market Cap
$6.03M
EBITDA Margin
-9081.41%
TTM Avg
-6199.48%
3Y Avg
-3862.58%
5Y Avg
-3269.64%
Market Cap
$6.72M
EBITDA Margin
-430.70%
TTM Avg
-678.73%
3Y Avg
-962.21%
5Y Avg
-5357.45%
Market Cap
$6.74M
EBITDA Margin
-9012.26%
TTM Avg
-10323.55%
3Y Avg
-8965.35%
5Y Avg
-8208.29%
Market Cap
$6.76M
EBITDA Margin
-10.17%
TTM Avg
-10.02%
3Y Avg
-12.29%
5Y Avg
-11.98%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biomerica, Inc. (BMRA) | $6.34M | -110.02% | -131.38% | -116.79% | -103.96% |
| Ensysce Biosciences, Inc. (ENSC)vs › | $6.44M | -485.73% | -485.73% | -485.73% | -485.73% |
| Femasys Inc. (FEMY)vs › | $6.10M | -729.87% | -884.05% | -981.20% | -851.95% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $6.10M | -41051.94% | -32118.88% | -145781.05% | -130042.11% |
| Enlivex Therapeutics Ltd. (ENLV)vs › | $6.09M | -417.17% | -417.17% | -417.17% | -417.17% |
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)vs › | $6.03M | -9081.41% | -6199.48% | -3862.58% | -3269.64% |
| Bolt Biotherapeutics, Inc. (BOLT)vs › | $6.72M | -430.70% | -678.73% | -962.21% | -5357.45% |
| Aclarion, Inc. (ACON)vs › | $6.74M | -9012.26% | -10323.55% | -8965.35% | -8208.29% |
| Enveric Biosciences, Inc. (ENVB)vs › | $6.76M | -10.17% | -10.02% | -12.29% | -11.98% |
| Co-Diagnostics, Inc. (CODX)vs › | $6.88M | -4847.72% | -2918.14% | -1630.06% | -1069.46% |
Gross Margin
8.1%
EBITDA Margin
-110.0%
Operating Margin
-119.5%
Net Margin
-84.8%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-05-31 | -162.51% |
| 2026-02-28 | -120.87% |
| 2025-11-30 | -104.96% |
| 2025-08-31 | -73.62% |
| 2025-05-31 | -194.93% |
| 2025-02-28 | -99.29% |
| 2024-11-30 | -54.58% |
| 2024-08-31 | -70.34% |
| 2024-05-31 | -128.23% |
| 2024-02-29 | -187.41% |
| 2023-11-30 | -96.81% |
| 2023-08-31 | -66.55% |
| 2023-05-31 | -158.16% |
| 2023-02-28 | -140.85% |
| 2022-11-30 | -106.62% |
| 2022-08-31 | -120.55% |
| 2022-05-31 | -27.41% |
| 2022-02-28 | -0.13% |
| 2021-11-30 | -22.22% |
| 2021-08-31 | -114.34% |
| 2021-05-31 | -132.71% |
| 2021-02-28 | -57.22% |
| 2020-11-30 | -118.25% |
| 2020-08-31 | -158.20% |
| 2020-05-31 | -14.57% |
| 2020-02-29 | -70.52% |
| 2019-11-30 | -25.34% |
| 2019-08-31 | -31.13% |
| 2019-05-31 | -62.62% |
| 2019-02-28 | -52.98% |
| 2018-11-30 | -29.38% |
| 2018-08-31 | -32.28% |
| 2018-05-31 | -52.85% |
| 2018-02-28 | -20.14% |
| 2017-11-30 | -15.09% |
| 2017-08-31 | -12.27% |
| 2017-05-31 | -20.41% |
| 2017-02-28 | -17.68% |
| 2016-11-30 | -11.28% |
| 2016-08-31 | -0.90% |
| 2016-05-31 | -16.13% |
| 2016-02-29 | -15.49% |
| 2015-11-30 | -13.07% |
| 2015-08-31 | -1.35% |
| 2015-05-31 | -0.03% |
| 2015-02-28 | -5.31% |
| 2014-11-30 | -16.51% |
| 2014-08-31 | -15.53% |
| 2014-05-31 | 0.02% |
| 2014-02-28 | 5.62% |
| 2013-11-30 | -21.44% |
| 2013-08-31 | -12.19% |
| 2013-05-31 | 4.76% |
| 2013-02-28 | -0.69% |
| 2012-11-30 | 16.15% |
| 2012-08-31 | 21.52% |
| 2012-05-31 | 7.12% |
| 2012-02-29 | 11.73% |
| 2011-11-30 | 14.70% |
| 2011-08-31 | 11.36% |
| 2011-05-31 | 1.87% |
| 2011-02-28 | 8.47% |
| 2010-11-30 | -12.23% |
| 2010-08-31 | 1.77% |
| 2010-05-31 | -10.47% |
| 2010-02-28 | 10.22% |
| 2009-11-30 | -25.31% |
| 2009-08-31 | 2.44% |
| 2009-05-31 | 1.38% |
| 2009-02-28 | 17.22% |
| 2008-11-30 | -7.64% |
| 2008-08-31 | 14.09% |
| 2008-05-31 | 14.21% |
| 2008-02-29 | 10.81% |
| 2007-11-30 | 2.22% |
| 2007-08-31 | 17.14% |
| 2007-05-31 | 14.38% |
| 2007-02-28 | 8.44% |
| 2006-11-30 | 9.66% |
| 2006-08-31 | 5.00% |
| 2006-05-31 | 5.49% |
| 2006-02-28 | 4.76% |
| 2005-11-30 | -1.88% |
| 2005-08-31 | -2.50% |
| 2005-05-31 | -1.03% |
| 2005-02-28 | 3.61% |
| 2004-11-30 | -3.99% |
| 2004-08-31 | -2.16% |
| 2004-05-31 | 3.32% |
| 2004-02-29 | 5.50% |
| 2003-11-30 | -4.36% |
| 2003-08-31 | -13.11% |
| 2003-05-31 | 3.80% |
| 2003-02-28 | 1.39% |
| 2002-11-30 | -5.09% |
| 2002-08-31 | -5.49% |
